CAR-T cell therapy is now FDA-approved for patients with acute lymphoblastic leukemia and non-Hodgkin lymphoma.
Penn Medicine is also studying CAR-T therapy for other forms of cancer and are currently enrolling appropriate patients into clinical trials.
CAR-T for Pediatric and Young Adult Leukemia
In August 2017, Kymriah™ became the first CAR-T cell therapy to be approved by the FDA. Developed here at Penn Medicine, Kymriah™ was approved to treat patients up to 25 years of age with B-cell acute lymphoblastic leukemia (ALL).
For more information or to schedule a consultation, please call 215-316-5127. If you or a loved one has ALL and is under 18 years old, Children’s Hospital of Philadelphia (CHOP) may be able to help. You can reach the Cancer Immunotherapy Program at CHOP at 267-426-0762.
CAR-T for Non-Hodgkin Lymphoma
In addition to leukemia, Kymriah™ is approved to treat adult patients with diffuse large B-cell lymphoma (DLBCL) – the most common form of non-Hodgkin lymphoma (NHL) – as well as high grade B-cell lymphoma and DLBCL arising from follicular lymphoma.
Yescarta™ is another CAR therapy approved by the FDA for treatment of this disease.
Penn Medicine is the only cancer center in the Philadelphia region approved to administer both Kymriah™ and Yescarta™ for patients with DLBCL. Our oncologists are world-renowned experts in treating patients with CAR-T cell therapy. To make an appointment with one of our physicians, please call 215-316-5127.
CAR-T for Other Cancers
Our success in personalized cellular therapy does not stop with leukemia and lymphoma. We are continuing to develop and test cancer vaccines, immune modulatory drugs and cell-based therapies for both blood and solid tumor cancers.
There are a number of CAR-T cell therapy clinical trials available at Penn Medicine for all different forms of cancer. View the list here.
To learn more about clinical trials, watch our video "What Is A Clinical Trial?".
You can also check out this short film, produced by Ross Kaufman, which details the story of the first pediatric patient, Emily Whitehead, to receive our CAR-T cell therapy: